Parkman Healthcare Partners LLC bought a new position in Boston Scientific Corporation (NYSE:BSX – Free Report) during the 2nd quarter, HoldingsChannel reports. The fund bought 180,481 shares of the medical equipment provider’s stock, valued at approximately $7,703,000.
Several other institutional investors have also added to or reduced their stakes in the company. Legal & General Group Plc bought a new stake in Boston Scientific in the 2nd quarter worth $431,890,000. The Manufacturers Life Insurance Company bought a new position in shares of Boston Scientific during the second quarter valued at about $115,346,000. Sone Capital Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $1,016,000. L2 Asset Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $362,000. Finally, Vega Investment Solutions bought a new stake in shares of Boston Scientific in the second quarter worth about $477,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.
Insider Activity
In other news, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 194,522 shares of company stock worth $9,385,210 in the last quarter. 0.34% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on Boston Scientific
Boston Scientific Price Performance
BSX stock opened at $48.98 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The firm has a 50-day moving average of $46.38 and a 200 day moving average of $57.32. The company has a market cap of $70.99 billion, a P/E ratio of 19.83, a PEG ratio of 1.10 and a beta of 0.56.
Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the firm posted $0.75 EPS. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.
Boston Scientific declared that its Board of Directors has initiated a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board of directors believes its shares are undervalued.
Boston Scientific Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles
- Five stocks we like better than Boston Scientific
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
